A Phase 3 interventional study of RNF and RNF in Multiple Sclerosis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 67 sites in 27 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-01-24.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 2nd largest by enrollment, is the only one that started in 2006, is one of 7 in phase 3, and was the 8th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 8 · Phase 4 15
First in 1999; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 517 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 85 across the 34 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany: none open now, 1 under way, none of them phase 3. Of 70 finished, 42 (60%) have results posted.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 5th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2006, is one of 11 in phase 3, and was the 4th registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 71 in Multiple Sclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.
The primary objective of the study is to evaluate the effect of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of Interferon [IFN] beta-1a (RNF) 44 microgram (three times weekly and once weekly) versus placebo on the time to conversion to McDonald multiple sclerosis (MS) criteria (2005) in subjects with a first clinical demyelinating event at high risk of converting to MS.
The main secondary objective of study is to evaluate the effect of RNF 44 microgram (three times weekly and once weekly) versus placebo on the "Time to conversion to clinically definite MS (CDMS)" in subjects with a first clinical demyelinating event at high risk of converting to MS.
At the end of 24 month double-blind core REFLEX trial, subjects who will not convert to CDMS and decide to receive open-label (OL) treatment will be enrolled into an open-label, 12 month extension period to evaluate the effect of RNF 44 mcg three times weekly treatment on the time to conversion to McDonald MS and time to conversion to CDMS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, subject must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RNF
Drug: RNF · Drug: Placebo
Drug: Placebo
Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
Also known as: Rebif
Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
Also known as: Rebif
Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)
The McDonald criteria use dissemination in time and space established by magnetic resonance image (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium-enhancing (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.
Time frame: Various time points from randomization up to 24 months
Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)
The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.
Time frame: Various time points from randomization up to 36 months
Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score
CDMS was defined by the occurrence of a second exacerbation or relapse over 24 months in participants who presented with first clinical demyelinating event (FCDE) accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
Time frame: Various time points from randomization up to 24 months
Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score
CDMS was defined by the occurrence of a second exacerbation or relapse over 36 months in participants who presented with FCDE accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
Time frame: Various time points from randomization up to 36 months
Mean Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Hypointense Lesions Per Participant Per Scan
Number of CUA lesions, new T2 lesions, Gd+ lesions and new T1 hypointense lesions were measured by using MRI scans.
Time frame: Month 24 up to Month 36
Change From Baseline in Time Constant 2 (T2) Lesion Volume , Time Constant 1 (T1) Hypointense Lesion Volume and Gadolinium Enhanced (Gd+) Lesion Volume at Month 36
Change from baseline in lesion volume was measured by using MRI scans for T2 lesions, T1 hypointense lesions and (Gd+) lesions.
Time frame: Baseline, Month 36
Change From Baseline in Expanded Disability Status Score (EDSS) Score at Month 36
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS at Month 36 was calculated as EDSS at Month 36 minus EDSS at baseline.
Time frame: Baseline, Month 36
The participants were recruited in 78 centers across 28 countries for REFLEX study. REFLEX 12 months open label extension (OLE) was conducted at 11 active centers in 9 countries.
| Milestone | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly | RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly | Placebo/OL RNF 44 Mcg Three Times Weekly | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 171 | 175 | 171 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 171 | 173 | 171 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 119 | 128 | 92 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 52 | 47 | 79 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 8 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Poor compliance | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Switched to open label phase | 31 | 30 | 59 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly | RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly | Placebo/OL RNF 44 Mcg Three Times Weekly | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 31 | 30 | 59 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 28 | 28 | 52 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 3 | 2 | 7 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly | RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly | Placebo/OL RNF 44 Mcg Three Times Weekly | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
The McDonald criteria use dissemination in time and space established by magnetic resonance image (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium-enhancing (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.
| days | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) |
|---|---|---|---|
| Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005) | 310 (183 to 488) | 182 (107 to 270) | 97 (93 to 101) |
CDMS was defined by the occurrence of a second exacerbation or relapse over 24 months in participants who presented with first clinical demyelinating event (FCDE) accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
| days | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) |
|---|---|---|---|
| Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
CDMS was defined by the occurrence of a second exacerbation or relapse over 36 months in participants who presented with FCDE accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
| days | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|
| Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Number of CUA lesions, new T2 lesions, Gd+ lesions and new T1 hypointense lesions were measured by using MRI scans.
| lesions | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|
| CUA lesions (n=3,5,9) | 0.33 ± 0.58 | 0.00 ± 0.00 | 1.56 ± 2.93 |
| New T2 lesions (n=3,5,9) | 0.17 ± 0.29 | 0.00 ± 0.00 | 0.94 ± 1.61 |
| New Gd+ lesions (n=3,5,9) | 0.17 ± 0.29 | 0.00 ± 0.00 | 0.56 ± 1.21 |
| New T1 Hypointense lesions (n=3,5,9) | 0.17 ± 0.29 | 0.00 ± 0.00 | 0.56 ± 0.88 |
Change from baseline in lesion volume was measured by using MRI scans for T2 lesions, T1 hypointense lesions and (Gd+) lesions.
| cubic millimeter (mm^3) | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|
| T2 lesion volume at Baseline (n=4,5,11) | 675.20 ± 940.87 | 1703.48 ± 1324.41 | 3533.37 ± 3914.98 |
| T2 lesion volume change at Month 36 (n=2,4,8) | 180.25 ± 198.34 | -22.63 ± 382.14 | -1155.63 ± 3348.36 |
| T1 lesion volume at Baseline (n=4,5,11) | 30.05 ± 60.10 | 302.70 ± 358.58 | 488.72 ± 589.06 |
| T1 lesion volume change at Month 36 (n=2,4,8) | 55.75 ± 78.84 | 216.68 ± 310.06 | 138.89 ± 339.99 |
| Gd+ lesion volume at Baseline (n=4,5,11) | 103.70 ± 151.17 | 0.00 ± 0.00 | 287.15 ± 649.68 |
| Gd+ lesion volume change at Month 36 (n=2,4,8) | -47.20 ± 66.75 | 0.00 ± 0.00 | -246.08 ± 848.99 |
The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.
| days | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|
| Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS at Month 36 was calculated as EDSS at Month 36 minus EDSS at baseline.
| unit on a scale | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|
| Baseline (n=4,5,11) | 1.88 ± 0.85 | 1.60 ± 0.96 | 1.64 ± 0.67 |
| Change at Month 36 (n=2,4,8) | -0.25 ± 1.06 | -0.63 ± 0.48 | -0.50 ± 0.65 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | — | 6/171 (3.5%) | 149/171 (87.1%) |
| RNF 44 Mcg Once Weekly (DB Population) | — | 8/173 (4.6%) | 156/173 (90.2%) |
| Placebo (DB Population) | — | 12/171 (7%) | 133/171 (77.8%) |
| RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly | — | 1/31 (3.2%) | 20/31 (64.5%) |
| RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly | — | 0/30 (0%) | 20/30 (66.7%) |
| Placebo/OL RNF 44 Mcg Three Times Weekly | — | 1/59 (1.7%) | 47/59 (79.7%) |
| RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | — | 0/4 (0%) | 3/4 (75%) |
| RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | — | 0/5 (0%) | 2/5 (40%) |
| Placebo/RNF 44 Mcg Three Times Weekly (OLE) | — | 0/11 (0%) | 5/11 (45.5%) |
| Event | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly | RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly | Placebo/OL RNF 44 Mcg Three Times Weekly | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|---|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/171 | 0/173 | 0/171 | 1/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| AppendicitisInfections and infestations | 3/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| Psychotic disorderPsychiatric disorders | 0/171 | 0/173 | 0/171 | 0/31 | 0/30 | 1/59 | 0/4 | 0/5 | 0/11 |
| Ovarian cystReproductive system and breast disorders | 0/171 | 0/173 | 2/171 | 0/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| TonsillitisInfections and infestations | 1/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| Gastrointestinal motility disorderGastrointestinal disorders | 0/171 | 0/173 | 1/171 | 0/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| Inguinal herniaGastrointestinal disorders | 0/171 | 0/173 | 1/171 | 0/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| Pancreatic necrosisGastrointestinal disorders | 0/171 | 0/173 | 1/171 | 0/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| Breast cancer stage IIINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/171 | 0/173 | 1/171 | 0/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/171 | 0/173 | 1/171 | 0/31 | 0/30 | 0/59 | 0/4 | 0/5 | 0/11 |
| Event | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly | RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly | Placebo/OL RNF 44 Mcg Three Times Weekly | RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE) | RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE) | Placebo/RNF 44 Mcg Three Times Weekly (OLE) |
|---|---|---|---|---|---|---|---|---|---|
| Influenza like illnessGeneral disorders | 93/171 | 122/173 | 34/171 | 8/31 | 3/30 | 24/59 | 1/4 | 1/5 | 1/11 |
| Injection site erythemaGeneral disorders | 50/171 | 34/173 | 3/171 | 4/31 | 3/30 | 13/59 | 0/4 | 0/5 | 0/11 |
| HeadacheNervous system disorders | 46/171 | 37/173 | 46/171 | 3/31 | 2/30 | 5/59 | 1/4 | 0/5 | 2/11 |
| SyncopeNervous system disorders | 0/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 1/4 | 0/5 | 0/11 |
| LymphopeniaBlood and lymphatic system disorders | 0/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 1/4 | 0/5 | 1/11 |
| HyperthyroidismEndocrine disorders | 0/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 1/4 | 0/5 | 1/11 |
| Aphthous stomatitisGastrointestinal disorders | 0/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 1/4 | 0/5 | 0/11 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 1/4 | 0/5 | 0/11 |
| ContusionInjury, poisoning and procedural complications | 0/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 1/4 | 0/5 | 0/11 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/171 | 0/173 | 0/171 | 0/31 | 0/30 | 0/59 | 1/4 | 0/5 | 0/11 |
| Age, Continuous(years) | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | Total |
|---|---|---|---|---|
| Mean | 30.6 ± 8.5 | 30.7 ± 8.1 | 30.9 ± 7.9 | 30.7 ± 8.2 |
| Age, Customized(participants) | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | Total |
|---|---|---|---|---|
| Less than 30 years | 86 | 86 | 87 | 259 |
| Greater than or equal to 30 years | 85 | 89 | 84 | 258 |
| Sex: Female, Male(Participants) | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | Total |
|---|---|---|---|---|
| Female | 114 | 106 | 112 | 332 |
| Male | 57 | 69 | 59 | 185 |
| Race/Ethnicity, Customized(participants) | RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) | RNF 44 Mcg Once Weekly (DB Population) | Placebo (DB Population) | Total |
|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 0 |
| Black | 0 | 1 | 0 | 1 |
| White | 171 | 174 | 171 | 516 |
| Other | 0 | 0 | 0 | 0 |
The record gives a start of Nov 2006, a primary completion of Aug 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Merck KGaA, Darmstadt, Germany →